- Rare presentations can suggest more than one rare condition: Striking personal and family cancer history in a patient with both CDKN2A and BRCA1 pathogenic variants.
- Trupiano N, Koeppe E, Jacobs MF, Else T, Cha KB.
- JAAD Case Rep. 2022 Nov 7 [eCollection 2023 Jan];31:42-45. doi: 10.1016/j.jdcr.2022.10.034.
- PMID: 36505034
- PubMed abstract
- Case report
- Free PMC article
- Free Full Text
- Pathogenic Variant Spectrum in Breast Cancer Risk Genes in Finnish Patients.
- Nurmi AK, Suvanto M, Dennis J, Aittomäki K, Blomqvist C, Nevanlinna H.
- Cancers (Basel). 2022 Dec 14;14(24):6158. doi: 10.3390/cancers14246158.
- Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients.
- Gurioli G, Tedaldi G, Farolfi A, Petracci E, Casanova C, Comerci G, Danesi R, Arcangeli V, Ravegnani M, Calistri D, Zampiga V, Cangini I, Fonzi E, Virga A, Tassinari D, Rosati M, Ulivi P, De Giorgi U.
- Int J Mol Sci. 2022 Dec 13;23(24):15789. doi: 10.3390/ijms232415789.
- Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.
- Michaelson-Cohen R, Cohen MJ, Cohen C, Greenberg D, Shmueli A, Lieberman S, Tomer A, Levy-Lahad E, Lahad A.
- Cancers (Basel). 2022 Dec 12;14(24):6113. doi: 10.3390/cancers14246113.
- Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
- Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R.
- Cancers (Basel). 2022 Dec 12;14(24):6117. doi: 10.3390/cancers14246117.
- Review
- Free Full Text
- Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer.
- Li C, Ye W, Zhou W, Ye Z, Yang W, Cheng Z.
- Front Oncol. 2022 Dec 12;12:1010158. doi: 10.3389/fonc.2022.1010158.
- Case report
- Free Full Text
- Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
- Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
- Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.
- SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib.
- Markman M.
- Medscape Oncology. Perspective. 2022 Dec 12.
- Video. Commentary
- Free Full Text
- Myriad Genetics Generates More Data on its PRS's Ability to Identify Who Will Develop Breast Cancer.
- Ray F.
- Precision Oncology News. 2022 Dec 12.
- News
- Free Full Text
- Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients-a systematic review and meta-analysis.
- Fazekas T, Széles ÁD, Teutsch B, Csizmarik A, Vékony B, Váradi A, Kói T, Lang Z, Ács N, Kopa Z, Hegyi P, Hadaschik B, Grünwald V, Nyirády P, Szarvas T.
- Prostate Cancer Prostatic Dis. 2022 Dec 12. doi: 10.1038/s41391-022-00626-2. Epub ahead of print.
- PMID: 36509931
- PubMed abstract
- Meta-Analysis
- Free Full Text
- Evaluation of external validity of the OVHIPEC-1 trial in a real-world population.
- van Stein RM, Sikorska K, van der Aa MA, Sonke GS, van Driel WJ; Dutch OVHIPEC-1 trial group.
- Int J Gynaecol Obstet. 2022 Dec 10. doi: 10.1002/ijgo.14618. Epub ahead of print.
- PMID: 36495280
- PubMed abstract
- Source abstract
- RE: Heterozygous BRCA1/BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
- Evans DG, Woodward ER.
- J Natl Cancer Inst. 2022 Dec 10:djac223. doi: 10.1093/jnci/djac223. Epub ahead of print.
- Letter, Commentary
- Free Full Text (PDF)
•• Letter, Reply:
Reply to Evans and Woodward.
•• Original research:
Heterozygous BRCA1 and BRCA2 and Mismatch Repair Gene Pathogenic Variants in Children and Adolescents With Cancer.
- PMID: 35980168
- PubMed abstract
- Free Full Text
- Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
- Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A.
- Breast Cancer Res Treat. 2022 Dec 9. doi: 10.1007/s10549-022-06822-x. Epub ahead of print.
- PMID: 36494460
- PubMed abstract
- CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
- Nyberg T, Brook MN, Ficorella L, Lee A, Dennis J, Yang X, Wilcox N, Dadaev T, Govindasami K, Lush M, Leslie G, Lophatananon A, Muir K, Bancroft E, Easton DF, Tischkowitz M, Kote-Jarai Z, Eeles R, Antoniou AC.
- J Clin Oncol. 2022 Dec 9:JCO2201453. doi: 10.1200/JCO.22.01453. Epub ahead of print.
- PMID: 36493335
- PubMed abstract
- Source abstract
- Cancer Moonshot 2.0, health equity and BRCA1/2 testing.
- Sorscher S.
- J Cancer Policy. 2022 Dec 8:100379. doi: 10.1016/j.jcpo.2022.100379. Epub ahead of print.
- PMID: 36503104
- PubMed abstract
- Source abstract
- Letter
- The BRCAness Landscape of Cancer.
- Guo M, Wang SM.
- Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
- PMID: 36497135
- PubMed abstract